iRhythm Technologies Files 8-K Report
Ticker: IRTC · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1388658
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
Related Tickers: IRTC
TL;DR
iRhythm filed a routine 8-K, nothing major to see here.
AI Summary
On January 13, 2025, iRhythm Technologies, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but the filing indicates standard reporting procedures.
Why It Matters
This 8-K filing indicates that iRhythm Technologies is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for Regulation FD Disclosure and Financial Statements, indicating routine corporate activity rather than a material event.
Key Players & Entities
- iRhythm Technologies, Inc. (company) — Registrant
- 0001388658-25-000003 (filing_id) — Accession Number
- January 13, 2025 (date) — Date of report
- 699 8th Street, Suite 600 San Francisco, California 94103 (address) — Principal executive office
- 415-632-5700 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported?
The date of the earliest event reported is January 13, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 699 8th Street, Suite 600, San Francisco, California 94103.
What is the Commission File Number for iRhythm Technologies, Inc.?
The Commission File Number for iRhythm Technologies, Inc. is 001-37918.
What is the IRS Employer Identification Number for the company?
The IRS Employer Identification Number for iRhythm Technologies, Inc. is 20-8149544.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-01-13 08:34:15
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 Per Share IRTC The NASDAQ Global Select
Filing Documents
- irtc-20250113.htm (8-K) — 26KB
- irtc_2025jpmconferencebu.htm (EX-99.1) — 8KB
- irtc_2025jpmconferencebu001.jpg (GRAPHIC) — 347KB
- irtc_2025jpmconferencebu002.jpg (GRAPHIC) — 183KB
- 0001388658-25-000003.txt ( ) — 895KB
- irtc-20250113.xsd (EX-101.SCH) — 2KB
- irtc-20250113_lab.xml (EX-101.LAB) — 22KB
- irtc-20250113_pre.xml (EX-101.PRE) — 13KB
- irtc-20250113_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On January 13, 2025, in connection with remarks to be made at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025 (the "Conference"), beginning at 7:30 p.m. Eastern Time/4:30 p.m. Pacific Time, the Company issued a press release announcing preliminary fourth quarter 2024 highlights and business updates, including updated financial outlook for fiscal year 2024 and financial outlook for fiscal year 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. This Form 8-K may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, an investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate', estimate', expect', intend', will', project', plan', believe', target' and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity and quality improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled "Risk Factors" and elsewhere in our filings made with the Securities and Exchange Commission, including those in iRhythm's most recent filings on Form 10-K, Form 10-Q and other SEC filings. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements. The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K,
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 P ress release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRHYTHM TECHNOLOGIES, INC. Date: January 13, 2025 By: /s/ Daniel Wilson Daniel Wilson Chief Financial Officer